Background: Acute Chest Syndrome (ACS) is one of the leading causes of death among children
individuals with SCD. Since the mechanisms accounting for this phenotypic variability are incompletely understood, improved knowledge could lead to better prevention and treatment of ACS. 1, 4 ACS results from a combination of aberrant multi-cellular interactions, many of which involve the endothelium, including adhesion, ischemia-reperfusion injury, infection, and inflammation. 2, 4 In patients with SCD, the endothelium is damaged by activated platelets, cell free hemoglobin, and heme, causing alterations that include decreased bioavailability of nitric oxide and increased inflammation. 5 Even in the absence of red blood cells, plasma from patients with SCD elicits unique (and potentially pathologic) changes in endothelial gene expression compared with non-SCD patients. 6 Recent evidence has shown that extracellular vesicles in plasma are paracrine effectors of endothelial function, suggesting their possible importance in the pathophysiology of ACS. 7 Extracellular vesicles (ECVs) with a diameter between 100 and 1000 nm are present in the circulation and have been shown to increase in SCD and impact disease pathogenesis. 8 Only rather limited studies have been conducted to examine the involvement of smallest ECVs, exosomes, in sickle cell pathophysiology. Exosomes are ECVs composed of bilayered proteolipids that contain selectively packaged, tissuespecific proteins, mRNAs, microRNAs, lipids, and occasionally DNA. 9 Exosomes are present in normal plasma, and their abundance is increased in patients with various pathologies, such as cancer and inflammatory disorders. 9 Exosomes can selectively bind to endothelium and enter the cells via transcytosis to deliver RNAs encoding inflammatory cytokines, regulatory microRNAs, and/or specific proteins that in turn modulate endothelial cell function, induce inflammation, alter gene expression, and enhance cellular migration, injury or death. 9 We recently showed that extracellular vesicles from SCD patients contain different miRNAs based on general SCD severity. 10 However, exosomes have not been evaluated as potential modulators of SCD phenotypic variance.
Accordingly, we hypothesized that circulating exosomes from patients with SCD who experienced one or more episodes of ACS (ACS(+)) would induce increased dysfunction of naïve endothelium in vitro as compared to exosomes from SCD patients who never experienced an ACS episode (ACS(−)). We evaluated this hypothesis in a convenience cohort of pediatric patients with SCD at the University of Chicago and LaRabida Children's Hospital.
| MATERIALS AND METHODS

| Patient characteristics
A total of 33 patients with SCD at the University of Chicago Comer or LaRabida Children's Hospital were prospectively enrolled, with parents providing informed consent, and assent being obtained in subjects ≥9 years of age. Controls (n = 6) were recruited from the general pediatric clinic, were of African-American ancestry, had a BMI <85th percentile, did not to carry a diagnosis of asthma or inflammatory disorder, and were having blood drawn for screening.
All protocols were approved by the IRB (protocol # 14-0466 and 15-0263) and were conducted in accordance with the guidelines set by the Declaration of Helsinki. Patients were excluded if less than 2 years of age, currently in an aplastic crisis, had a previous stroke, or were receiving chronic transfusion therapy. All patients were in a steadystate of disease (free of infection, new pain, or transfusion for the 4 weeks prior to their participation). Clinical and demographic characteristics of SCD patients and controls are shown in Table 1 and supplementary Table S1 , respectively. After clinically necessary blood work, 6 mL of blood were drawn in EDTA, centrifuged at 2000g
at 4°C for 20 min and platelet-free plasma was separated and frozen at −80°C until further use.
| Event characteristics
ACS was defined as a new infiltrate on chest X-ray accompanied by fever, supplemental oxygen requirement, tachypnea, wheezing, 
| Exosome isolation
Exosomes were isolated from plasma using the Total Exosome Isolation kit from Life Technologies (Carlsbad, CA) per manufacturer's guidelines. All downstream experiments were performed with exosomes at a 1:100 dilution based on sensitivity curves determined previously. 10 Detailed procedure in supplemental methods. 
| Exosome quantification and cellular origin
| eNOS expression
Exosomes were added to HMVEC cells that had been grown to confluent after seeding at 3 × 10 5 . RNA was isolated with Qiagen RNeasy mini kit (Qiagen, Crawley, UK). DNase-treated mRNA was reverse-transcribed using the high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA). Expression of eNOS was determined by real-time quantitative PCR using assay-on-demand primer sets were analyzed using ABI7500 SDS version 2 (Applied Biosystems). The relative expression of eNOS was normalized to GAPDH using the ΔCT method and expressed as the relative quantity(RTL).
3 | RESULTS
| Clinical characteristics
Thirty-three patients with SCD completed the study. The demographic, hematologic, and clinical characteristics of ACS(−) and ACS(+) patients are shown in Table 1 90.05 ± 2.28; P = 0.006) were significantly higher in ACS(+) patients (Table 1) .
| Exosomes in SCD
Plasma exosomes were isolated from the 33 patients in the outpatient clinic, while at baseline. We quantified the exosomes originating from Similarly, the numbers of exosomes derived from each cell type in patients with SCD was increased significantly (Fig. 1B) . Although there was significant variability between patients, erythrocyte-derived exosomes exhibited the highest increase, with an overall threefold increase from control to SCD ( Fig. 1B ; controls: 9661 ± 3195/100 uL vs SCD: 31 338 ± 5,323/100 uL, P < 0.007). Endothelial cell-derived exosomes also revealed marked differences between SCD and controls ( Fig. 1B ; controls: 814 ± 45/100 uL vs SCD 1967 ± 255/ 100 uL, P < 0.0001). Platelet exosomes were the only subtype where an increase was observed but did not reach significance ( Fig. 1B; controls 1116 ± 350 vs SCD 2702 ± 670, P = 0.0535).
In contrast to the marked increase of exosome numbers observed between SCD patients and controls, we observed only minor differences in the exosome numbers between SCD patients with or without ACS. No significant differences were detected in the abundant exosomes from erythroid, hematopoietic progenitor, or lymphocyte origins between ACS(+) and ACS(−) (Fig. 1C) . In contrast, there was a significant increase in monocyte-derived exosomes between ACS(−) and ACS(+) which correspond to a small fraction of the total exosome population ( 
| Endothelial impedance changes after exposure to exosomes
To evaluate potential functional differences between the exosomes from ACS(−) and ACS(+) patients in a qualitative manner, we treated human microvascular endothelial cell monolayers with exosomes from each patient, and monitored the effects on the integrity of the monolayers using an endothelial impedance assay. In Fig 
| Effects of exosomes on eNOS gene expression
Since no tissue-specific differences were detected in exosomes derived from patients with SCD, we evaluated which aspect of endothelial integrity might be regulated by exosomes. Knowing that exosomes have previously been shown to impact ischemia-reperfusion injury via PISKT/eNOS, we tested eNOS expression 24 h after endothelial cells were exposed to exosomes. 11 After exposure to exosomes, naïve endothelial cells displayed divergent changes in the expression of eNOS (Fig. 3A) . We restricted our analysis to patients with HgbSS and HgbS-O-Arab since they demonstrated a significant differential based on ACS status in endothelial monolayer impedance testing (Fig. 2D) . We additionally restricted the analysis to children older than 10 in order to better age-match the groups. Exosomes from controls yielded no significant changes in eNOS expression when compared to basal expression levels in untreated endothelial cells. 
| DISCUSSION
In the present pilot study, we have shown that the plasma from patients with SCD contains a much higher concentration of exosomes than that of control patients. While microparticles are known to be produced at higher rates in SCD, limited knowledge exists about exosomes in SCD. 8 The exosomes identified in this study derive from a variety of hematopoietic and endothelial cell sources, but most prominently from erythrocytes. The exosomes from SCD patients in our study exert variable effects on endothelial integrity in vitro depending on the ACS history of (C) Number of exosomes from each cellular origin in patients with SCD that did not experience ACS (ACS−) versus those with a history of (ACS+) episodes. *P < 0.05, **P < 0.005, and ***P < 0.0005 platelets. 12 Among the exosomes from SCD patients there were few significant differences in cellular origin based on history of ACS.
Notably, there were increased monocyte-derived exosomes from the ACS(+) patients compared to the ACS(−) patients. Although they made up a small fraction of the total exosomes, they are intriguing because monocytes are capable of targeting specific tissues.
SCD is a disease of baseline inflammation and endothelial damage making it rare to find markers of disease at baseline that are not already and serve as disease phenotype biomarkers. 13 Exosomes contain multiple elements that are potentially biologically active (miRNA, proteins, and lipids). 9, [14] [15] [16] In subsequent studies, it will be important to identify exosome contents that underlie the preponderant biological differences identified in our experiments.
In addition to detecting a difference between ACS(+) and ACS(−)- Occlusion occurs in a regular, but intermittent pattern, exposing vessels to the dual effects of hypoxia, and re-oxygenation mimicking ischemiareperfusion injury. Exosomes isolated from cultured cells treated with hypoxia contain altered miRNA profiles and produce barrier protection of endothelial cells in vitro. 17 Exosomes have been previously shown to demonstrate protective effects after ischemia-reperfusion injury and carry non-target effects of ionizing radiation, but never both. [18] [19] [20] [21] In our study, exosomes from patients with SCD afforded both protective and damaging effects, diverging based on the severity of disease and genotype; exosomes from ACS(−) patients promoted continued growth of the endothelial monolayer and from ACS(+) patients, exosomes caused endothelial damage. We speculate that there may be differing miRNAs responsible for these differential effects.
To test our hypothesis that exosomes in the setting of SCD induced ischemia-reperfusion injury act via PISKT/eNOS, we tested eNOS expression 24 h after endothelial cells were exposed to exosomes. ENOS is a critical regulator of nitric oxide and consequently of endothelial integrity. It contributes to leukocyte adhesion, vascular tone, and platelet aggregation-all of which are critical in the pathogenesis of SCD. 22 In murine models of whole body hypoxic preconditioning, eNOS is selectively increased (as opposed to inducible or neural NOS), and induces anti-inflammatory protection. 23 Interestingly, when that protective mechanism is not available, such as in eNOS knock-out mice, pulmonary ischemia results in severe pulmonary edema. 24 In humans, at least one eNOS polymorphism is associated with an increased risk of ACS in females with SCD. 25 Our data provide a novel insight into a method of intercellular communication in SCD that can be harnessed to improve outcomes.
While further work needs to be done, with a large multi-institutional cohort, there is potential to utilize exosomes to predict which patients may develop ACS and to tailor therapy. It is clear that exosomes in patients with SCD have differential effects based on their disease state. With a better understanding of patient-specific and treatmentspecific effects we could potentially increase production of protective exosomes. Our next steps include evaluating all the pathways that are regulated by exosomes in SCD and evaluating how we can clinically modulate those pathways.
